ClinicalTrials.gg
Not yet recruitingNCT07538466Updated Apr 20, 2026

A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232

A Phase 1 interventional study of AD-123 and AD-1231 and AD-1232 in Diabetes Mellitus, sponsored by Addpharma Inc.. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 224 studies in Diabetes Mellitus with a site in Korea, Republic of — 22 open to participants now, 25 under way, 3 of them phase 3. Diabetes Mellitus · Korea, Republic of.

Planned enrollment
136th of 181
50 · median 140
Started
2026
with 4 others
Phase 1
26 of 224
3 open now
Primary completion
2026-05
later than 9 of 24 live
Registered
223rd of 224
by date

Among the 224 studies in Diabetes Mellitus with a site in Korea, Republic of, this one is the 136th largest by planned enrollment of the 181 interventional ones that give a count, is one of 5 that started in 2026, is one of 26 in phase 1, reaches primary completion later than 9 of the 24 other live ones, and was the 223rd registered.

Diabetes Mellitus

8,294 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

22 of the 224 studies in Diabetes Mellitus with a site in Korea, Republic of are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 224 studies in Diabetes Mellitus with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
  • The Age equal to or greater than 19 in healthy volunteers at the time of screening visit

Exclusion criteria

Exclusion Criteria:

  • Participation in another clinical study with an drug within the 6 months from scheduled first administration
  • Other exclusions applied
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Sequence A (RT)

    Period 1 : Reference Drug(AD-1231 and AD-1232), Period 2 : Test Drug(AD-123)

    Drug: AD-123 · Drug: AD-1231 and AD-1232

  • Experimental
    Sequence B (TR)

    Period 1 : Test Drug(AD-123), Period 2 : Reference Drug(AD-1231 and AD-1232)

    Drug: AD-123 · Drug: AD-1231 and AD-1232

Interventions

  • DrugAD-123

    AD-123 Oral Tablet

  • DrugAD-1231 and AD-1232

    AD-1231 Oral Tablet + AD-1232 Oral Tablet

06

What researchers measure

Primary outcomes

  1. Maximum concentration of drug in plasma (Cmax)

    Cmax of AD-123

    Time frame: pre-dose to 72 hours

  2. Area under the plasma concentration-time curve during dosing interval (AUCt)

    AUCt of AD-123

    Time frame: pre-dose to 72 hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for May 2026, 1 month later.

Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's planned 1 month is below that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2026
First posted
Apr 20, 2026
StartEst.
Apr 2026
Primary completionEst.
May 2026
CompletionEst.
May 2026
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07538466
Lead sponsor
Addpharma Inc.
Responsible party
Sponsor
First posted
Apr 20, 2026
Start date
Apr 2026 (estimated)
Primary completion
May 2026 (estimated)
Completion
May 2026 (estimated)
Last update
Apr 20, 2026

Study contacts

Dasom Kim
Contact
dskim@addpharma.co.kr
+82-31-891-5572

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion